Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: A meta-analysis of diagnostic test characteristics

Hepatology

Volumn 26, Issue 4, 1997, Pages 1035-1044

  Bonis, Peter A L ^a,d   Ioannidis, John P A ^a,b   Cappelleri, Joseph C ^a,c   Kaplan, Marshall M ^a   Lau, Joseph ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; LYMPHOBLAST INTERFERON;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC TEST; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; META ANALYSIS; PRIORITY JOURNAL;

EID: 0030848422     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510260436     Document Type: Article

References (134)

1. Arase Y, Kumada H, Chayama K, Tsubota A, Ikeda K, Saitoh S, Sakai Y, et al. Alanine aminotransferase and HCV-RNA responses following interferon therapy of HCV-RNA positive chronic hepatitis. Gastroenterol Jpn 1992;27:646-651.
2. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Hepatitis Interventional Therapy Group, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
3. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. HEPATOLOGY 1992;15:1013-1016.
4. Bresci G, Parisi G, Banti S, Bertoni M. Therapy of active chronic hepatitis with recombinant alpha 2b-interferon: an 18 month follow-up. Eur J Med 1993;2:349-352.
5. Budillon G, Cimino L, Del Vecchio Blanco C, Mazzacca G, Iaquinto G, D'Ascoli B, Lampasi F, et al. Long-term follow-up evaluation in HCV chronic hepatitis treated with alpha-2b interferon. A comparison of two protocols. Ital J Gastroenterol 1994;26:16-20.
6. Caporaso N, Suozzo R, Morisco F, M DA, Romano M, Coltorti M. Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year. Ital J Gastroenterol 1993;25:482-486.
7. Douglas DD, Rakela J, Lin HJ, Hollinger FB, Taswell HF, Czaja AJ, Gross JB, et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Dig Dis Sci 1993;38:601-607.
8. Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamura K. A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C. Am J Gastroenterol 1995;90: 1246-1249.
9. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study. Dig Dis Sci 1993;38:612-618.
10. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, Di Napoli A, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. HEPATOLOGY 1993;18:1300-1305.
11. Marcellin P, Boyer N, Degott C, Martinot-Peignoux M, Duchatelle V, Giostra E, Areias J, et al. Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon. Liver 1994;14:302-307.
12. Lampertico P, Rumi M, Romeo R, Craxi A, Soffredini R, Biassoni D, Colombo M. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C. HEPATOLOGY 1994;19:19-22.
13. Vento S, Concia E, Ferraro T. Lack of sustained efficacy of interferon in patients with chronic hepatitis C [Letter]. N Engl J Med 1996;334: 1479-1480.
14. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med 1993;119:110-115.
15. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, National Heart, Lung, and Blood Institute Study Group, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911.
16. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
17. McCormick S, Goodman Z, Maydonovitch C, Sjorgren M. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol 1996;91:1516-1522.
18. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
19. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Multicenter Study Group, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis (published erratum appears in N Engl J Med 1996;334:1143). N Engl J Med 1995;332:1457-1462.
20. Shiffman M, Hofmann C, Ferreira-Gonzalez A, Contos M, Luketic V, Thompson E, Saynal A, et al. Histologic response to interferon alpha-2b (INF) is associated with a decline in HCV-RNA titer in patients with chronic hepatitis C virus (HCV) [Abstract]. HEPATOLOGY 1996; 24:157A.
21. Mathurin P, The'venot T, Sobewski R, Moussali J, Charlotte F, Opolon P, Poynard T. Six months with inteferon alpha (IFN) decrease the progression of liver fibrosis and activity in patients with chronic hepatitis C without normalization of ALT at 3 months [Abstract]. HEPATOLOGY 1996;22:157A.
22. Rizzetto M, Goldin R, Marcellin P, Farrell G, Bacon B, Mosteller M, Howe I, et al. Correlations between virologic and histologic responses in chronic hepatitis C patients: analyses from a large international comparative study of alpha-interferon therapy [Abstract]. J Hepatol 1996;24:57A.
23. Camma' C, Linea C, Giunta M, Almasio P, Craxi A, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis [Abstract]. J Hepatol 1996; 24:143A.
24. Alter M. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14.
25. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
26. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Hepatitis Interventional Therapy Group, et al. Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. J Hepatol 1990;11:S31-S35.
27. DiBisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Goodman Z, Banks SM, Hoofnagle JH. A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy for chronic non-A, non-B (type C) hepatitis. J Hepatol 1990;11:536-42.
28. Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC Jr, Balart LA, Hepatitis Interventional Therapy Group, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. Gastroenterology 1993;104:595-603.
29. Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trepo C, Grimaud JA. Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. HEPATOLOGY 1993;18:1344-1349.
30. Makris M, Preston FE, Triger DR, Underwood JC, Westlake L, Adelman MI. A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs. Blood 1991;78:1672-1677.
31. Makris M, Preston FE, Triger DR, Underwood JC, Westlake L, Adelman MI. Interferon alfa for chronic hepatitis C in haemophiliacs. Gut 1993;34:S121-S123.
32. Saracco G, Rosina F, Torrani Cerenzia MR, Lattore V, Chiandussi L, Gallo V, Petrino R, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990; 11:S43-S49.
33. Schvarcz R, Weiland O, Wejstal R, Norkrans G, Fryden A, Foberg U. A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis 1989;21:617-625.
34. Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstal R, Fryden A. Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis. Liver 1991;11:30-38.
35. Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstal R, Fryden A. Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders. Scand J Infect Dis 1991;23:413-420.
36. Weiland O, Schvarcz R, Wejstal R, Norkrans G, Fryden A. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience. J Hepatol 1990;11:S57-S62.
37. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
38. French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. HEPATOLOGY 1994;20:15-20.
39. De Groote J, Desmet VJ, Gedigk P, Korb G, Popper H, Poulsen H, Scheuer PJ, et al. A classification of chronic hepatitis. Lancet 1968;2: 626-628.
40. Popper H, Schaffner F. The vocabulary of chronic hepatitis. N Engl J Med 1971;284:1154-1156.
41. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374.
42. Hopf U, Kuther S, Konig V, Heuft H, Berg T, Bauditz J, Soltani K, et al. Long-term follow-up of chronic hepatitis C after treatment with recombinant interferon alpha-2a. Z Gastroenterol 1994;32:425-430.
43. Mulrow CD, Linn WD, Gaul MK, Pugh JA. Assessing quality of a diagnostic test evaluation. J Gen Intern Med 1989;4:288-295.
44. Gray R, Begg CB, Greenes RA. Construction of receiver operating characteristic curves when disease verification is subject to selection bias. Med Decis Making 1984;4:151-164.
45. Swets J. Measuring the accuracy of diagnostic systems. Science 1988; 240:1285-1293.
46. Shapiro DE. Issues in combining independent estimates of the sensitivity and specificity of a diagnostic test. Acad Radiol 1995;2:S37-S47.
47. Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. Med Decis Making 1993;13:313-321.
48. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993;12:1293-1316.
49. Hurblut T, Littenberg B. The diagnostic accuracy of rapid dipstick tests to predict urinary tract infection. Am J Clin Pathol 1991;96:582-588.
50. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141:680-689.
51. Cox DR, Scnell E. Analysis of Binary Data. 2nd ed. New York: Chapman and Hall, 1989.
52. Reichard O, Glaumann H, Norkrans G, Wejstal R, Fryden A, Schvarcz R, Weiland O. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course. Liver 1994;14: 169-174.
53. Angelini G, Sgarbi D, Colombari R, Bezzi A, Castagnini A, de Berardinis F, Conti A, et al. Alpha-interferon treatment of chronic hepatitis C: a controlled, multicentre, prospective study. Digestion 1995;56:199-203.
54. Balart LA, Perrillo R, Roddenberry J, Regenstein F, Shim KS, Shieh YS, Taylor B, et al. Hepatitis C RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment. Gastroenterology 1993;104:1472-1477.
55. Castilla A, Camps-Bansell J, Civeira MP, Prieto J. Lymphoblastoid alpha-interferon for chronic hepatitis C: a randomized controlled study. Am J Gastroenterol 1993;88:233-239.
56. Diodati G, Bonetti P, Noventa F, Casarin C, Rugge M, Scaccabarozzi S, Tagger A, et al. Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial. HEPATOLOGY 1994;19:1-5.
57. Hosoda K, Yokosuka O, Kato N, Ito Y, Ohto M, Omata M. Long-term effects of alpha-interferon for treatment of chronic hepatitis C in terms of histological changes with aminotransferase normalization and hepatitis C virus RNA seroconversion. Gastroenterol Jpn 1993;28:115-117.
58. Hiramatsu N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Haruna Y, Naito M, et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 1995;22:135-142.
59. Picciotto A, Callea F, Varagona G, Bardellini E, Borzone S, De Conca V, Vallarino E, et al. Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses. Liver 1995;15:20-24.
60. Reichen J, Solioz M, Buhler H, Gonvers JJ, Knoblauch M, Lavanchy D, Male PJ, et al. Low-dose interferon in chronic hepatitis non-A/non-B: effects on quantitative liver function and structure in a randomized, controlled multicenter trial. Clin Invest 1993;71:888-893.
61. Sieck JO, Ellis ME, Alfurayh O, Ali MA, Ali HA, Ayub A, al-Fadda M, et al. Histologically advanced chronic hepatitis C treated with recombinant alpha-interferon: a randomized placebo-controlled double-blind cross-over study. J Hepatol 1993;19:418-423.
62. Villari D, Raimondo G, Freni MA, Rodino G, Aiello A, Fava A, Longo G, et al. Histological behaviour of chronic hepatitis in patients treated with alpha interferon. Pathology 1992;24:243-246.
63. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990;6:5-30.
64. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd Ed. New York: Wiley, 1981:138-159.
65. Snedecor GW, Cochran WG. Statistical methods. Ames: Iowa State University, 1980:186-188.
66. Bresci G, Del Corso L, Romanelli AM, Giuliano G, Pentimone F. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis. J Am Geriatr Soc 1993;41:857-862.
67. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, et al. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-1578.
68. Picciotto A, Varagona G, Valle F, Coviello DA, Lapertosa G, Celle G. Interferon therapy in chronic hepatitis C. Evaluation of a low dose maintenance schedule in responder patients. J Hepatol 1993;17:359-363.
69. Ross AG, Burt MJ, Jennings LC, Collett JA, Walford EJ, Chambers ST, Chapman BA. Treatment of chronic hepatitis C with interferon alpha. N Z Med J 1995;108:101-103.
70. Sata M, Atono Y, Nakano H, Morita Y, Hino T, Ide T, Yano Y, et al. Effectiveness of 6-month intermittent administration of natural human interferon-alpha against non-A non-B chronic hepatitis. Kansenshogaku Zasshi 1992;66:667-678.
71. Angelico M, Gandin C, Pescarmona E, Rapicetta M, Del Vecchio C, Bini A, Spada E, et al. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995;90:263-269.
72. Boucher E, Jouanolle H, Andre P, Ruffault A, Guyader D, Moirand R, Turlin B, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. HEPATOLOGY 1995;21:322-327.
73. Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J. Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol 1993;17:390-396.
74. Capra F, Casaril M, Gabrielli GB, Tognella P, Rizzi A, Dolci L, Colombari R, et al. Alpha-interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers. J Hepatol 1993;18: 112-118.
75. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, TriVeneto Viral Hepatitis Group, et al. Randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. HEPATOLOGY 1995;22:700-706.
76. David E, Pucci A, Palladin D, Saracco G, Garello E, Pintus C, Rocca G, et al. Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A,non-B viral hepatitis. A randomized controlled trial. Am J Clin Pathol 1992; 98:397-401.
77. de Alava E, Camps J, Pardo-Mindan J, Garcia-Granero M, Munoz M, Sola J, Civeira MP, et al. Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alfa interferon. Liver 1993;13:73-79.
78. Gomez-Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreno V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol 1990;11:S63-S67.
79. Ferenci P, Vogel W, Pristautz H, Deimer J, Denk H, Judmaier G, Maier KP, et al. One-year treatment of chronic non-A, non-B hepatitis with interferon alfa-2b. J Hepatol 1990;11:S50-S53.
80. Fernandez I, Castellano G, Canga F, Colina F, Garcia H, Fuertes A, Casis B, et al. A comparative randomized controlled study of the efficacy of interferon alfa-2b and interferon alfa-2a in the treatment of chronic hepatitis C. Gastroenterol Hepatol 1995;18:66-72.
81. Guechot J, Loria A, Serfaty L, Giral P, Giboudeau J, Poupon R. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol 1995;22:22-26.
82. Kakumu S, Arao M, Yoshioka K, Hayashi H, Kusakabe A, Hirofuji H, Kawabe M. Recombinant human alpha-interferon therapy for chronic non-A, non-B hepatitis: second report. Am J Gastroenterol 1990;85: 655-659.
83. Kakumu S, Arao M, Yoshioka K, Ichimiya H, Murase K, Aoi T, Kusakabe A. Pilot study of recombinant human alpha-interferon for chronic non-A, non-B hepatitis. Am J Gastroenterol 1989;84:40-45.
84. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. HEPATOLOGY 1995;21:291-297.
85. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. HEPATOLOGY 1991;13:393-397.
86. Mazzella G, Salzetta A, Casanova S, Morelli MC, Villanova N, Miniero R, Sottili S, et al. Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response. Dig Dis Sci 1994;39:866-870.
87. Nakano Y, Kiyosawa K, Sodeyama T, Tanaka E. Comparative study of clinical, histological, and immunological responses to interferon therapy in type non-A, non-B, and type B chronic hepatitis. Am J Gastroenterol 1990;85:24-29.
88. Okazaki T, Yoshihara H, Suzuki K, Yamada Y, Tsujimura T, Kawano K, Yamada Y, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994;29:1039-1043.
89. Omata M, Ito Y, Yokosuka O, Imazeki F, Tagawa M, Takano S, Hosoda K, et al. Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant alpha-interferon for chronic non-A, non-B hepatitis. Dig Dis Sci 1991;36:1217-1222.
90. Panella C, Francavilla A, Conte D, Tatulli I, Rubini F. Clinical and histological evaluation of interferon alfa-2b in the treatment of chronic hepatitis C. Gut 1993;34:S127.
91. Passariello N, Sepe J, Peluso A, Carlino F, Guglielmelli V, Esposito P, Rossiello R, et al. Treatment of chronic hepatitis C with lymphoblastic interferon. Long-term follow-up. Presse Med 1995;24:1201-1206.
92. Perez R, Pravia R, Linares A, Gonzalez M, Rodriguez M, Lombrana JL, Riestra S, et al. Treatment of chronic hepatitis C with recombinant interferon alfa-2b for nine months. Gut 1993;34:S136-S138.
93. Poynard T, Bedossa P, Mathurin P, Naveau S, Delfraissy JF, Lemaigre G, Chaput JC. Efficacy of long term recombinant interferon-alfa in patients with chronic hepatitis C. A clinical, biological, histological and immunohistological study. Gastroenterol Clin Biol 1991;15:615-619.
94. Realdi G, Diodati G, Bonetti P, Scaccabarozzi S, Alberti A, Ruol A. Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial. J Hepatol 1990;11:S68-S71.
95. Romeo R, Pol S, Berthelot P, Brechot C. Eradication of hepatitis C virus RNA after alpha-interferon therapy. Ann Intern Med 1994;121: 276-277.
96. Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, Carreno V. High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. HEPATOLOGY 1991;13:327-331.
97. Suou T, Hosho K, Kishimoto Y, Horie Y, Kawasaki H. Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa. HEPATOLOGY 1995;22:426-431.
98. Terranova R, Luca S. Treatment of chronic hepatitis C with recombinant interferon alpha 2b. J Chemother 1992;4:297-302.
99. Uchida T, Taira M, Shikata T, Moriyama M, Tanaka N, Okubo H, Arakawa Y. Histological difference between complete responders and non-responders to interferon therapy of the livers of patients with chronic hepatitis C. Acta Pathol Jpn 1993;43:230-236.
100. Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 1994;7:165-168.
101. Villa E, Buttafoco P, Merighi A, Grottola A, Ferretti I, Ferrari A, Callea F, et al. Selection of more pathogenic hepatitis C virus genotype II during long-term follow-up of interferon-treated patients. J Mol Med 1995;73:249-254.
102. Yabu K, Kiyosawa K, Mori H, Matsumoto A, Yoshizawa K, Tanaka E, Furuta S. Serum collagen type IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C. Scand J Gastroenterol 1994;29:474-479.
103. Iino S, Hino K, Kondo T, Koike K, Yasuda K, Yotsuyanagi H, Kurokawa K. Interferon therapy for non-A, non-B chronic hepatitis. Gastroenterol Jpn 1991;26:224-229.
104. Kakumu S, Yoshika K, Tanaka K, Higashi Y, Kurokawa S, Hirofuji H, Kusakabe A. Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C. J Med Virol 1993;41:65-70.
105. Okuno T, Shindo M, Arai K, Matsumoto M, Takeda M. Histological improvement of chronic hepatitis B, and non-A, non-B with interferon treatment: application of a numerical scoring system for evaluating sequential morphologic changes. Gastroenterol Jpn 1990;25:70-77.
106. Shindo M, Arai K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy. Ann Intern Med 1995;122:586-591.
107. Liang TJ, Rustgi V, Galun E, Blum HE. HCV RNA in patients with chronic hepatitis C treated with interferon-alpha. J Med Virol 1993; 40:69-75.
108. Takeda T, Kuroki T, Fukuda K, Yabusako T, Nishiguchi S, Nakajima S, Shiomi S, et al. Long-term therapeutic efficacy of interferon for patients with chronic hepatitis C. Gastroenterol Jpn 1993;28:104-108.
109. Davis GL, Lau JY. Choice of appropriate end points of response to interferon therapy in chronic hepatitis C virus infection. J Hepatol 1995;22:110-114.
110. Orito E, Mizokami M, Suzuki K, Ohba K, Ohno T, Mori M, Hayashi K, et al. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995;46:109-115.
111. Camps J, Garcia-Granero M, Riezu-Boj JI, Larrea E, de Alava E, Civeira MP, Castilla A, et al. Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol 1994; 21:4-11.
112. Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, Fusamoto H, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994;39:977-982.
113. Hino K, Sainokami S, Shimoda K, lino S, Wang Y, Okamoto H, Miyakawa Y, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994;42:299-305.
114. Hasui T, Shimomura H, Tsuji H, Wato M, Tsuji T. Quantitation of hepatitis C virus RNA in liver tissue as a predictive marker of the response to interferon therapy in chronic hepatitis C. Acta Med Okayama 1994;48:151-157.
115. Orito E, Mizokami M, Nakano T, Terashima H, Nojiri O, Sakakibara K, Mizuno M, et al. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C. J Med Virol 1994;44:410-414.
116. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Oshita M, Katayama K, et al. Pretreatment viral load and response to prolonged interferon-alpha course for chronic hepatitis C. J Hepatol 1995;22: 457-463.
117. Garson JA, Brillanti S, Whitby K, Foli M, Deaville R, Masci C, Miglioli M, et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol 1995;45:348-353.
118. Kleter GE, Brouwer JT, Heijtink RA, Schalm SW, Quint WG. Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon. Antimicrob Agents Chemother 1993;37:595-597.
119. Kanai K, Kako M, Aikawa T, Kumada T, Kawasaki T, Hatahara T, Oka Y, et al. HCV RNA monitoring for tailored regimens of interferon therapy in hepatitis C. Biomed Pharmacother 1995;49:65-67.
120. Gerweck KK, Cheung AM, Wong DHK. Comparison of biochemical and virological responses to interferon therapy in chronic hepatitis C: a meta-analysis [Abstract]. HEPATOLOGY 1995;22:420A.
121. Lau JY, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet 1993;342:1208-1209.
122. Abdi W, Millan JC, Mezey E. Sampling variability on percutaneous liver biopsy. Arch Intern Med 1979;139:667-669.
123. Sheehan M, Doyle C, Kenny-Walsh E, Cannon B, Whelton M, Kirwan W, Whelton M. Histological changes in the right and left lobes of the liver in chronic hepatitis C: inflammatory change is evenly distributed [Abstract]. Gastroenterology 1996;110:1320A.
124. Soloway RD, Baggenstoss AH, Schoenfield LJ, Summerskill WH. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 1971;16:1082-1086.
125. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994;19:1513-1520.
126. Mattsson L, Weiland O, Glaumann H. Application of a numerical scoring system for assessment of histological outcome in patients with chronic posttransfusion non-A, non-B hepatitis with or without antibodies to hepatitis C. Liver 1990;10:257-263.
127. Scheuer PJ. The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995;22:112-114.
128. Terminology of chronic hepatitis, hepatic allograft rejection, and nodular lesions of the liver: summary of recommendations developed by an international working party, supported by the World Congresses of Gastroenterology, Los Angeles, CA, 1994. AmJ Gastroenterol 1994; 89:5177-5181.
129. Ludwig J. The nomenclature of chronic active hepatitis: an obituary. Gastroenterology 1993;105:274-278.
130. Vaquer P, Canet R, Llompart A, Riera J, Obrador A, Gaya J. Histological evolution of chronic hepatitis C. Factors related to progression. Liver 1994;14:265-269.
131. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, et al. The long-term pathological evolution of chronic hepatitis C. HEPATOLOGY 1996;23:1334-1340.
132. Banner BF, Barton AL, Cable EE, Smith L, Bonkovsky HL. A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. Mod Pathol 1995;8:232-238.
133. Ziol M, Nhieu J, Roudot-Thoraval F, Me'treau J, Deugnier Y, Dhumeauz D, Zafrani E. A histopathological study of the effects of 6-months versus 12-month interferon alpha-2b in chronic hepatitis C. J Hepatol 1996;25:833-841.
134. Reichard O, Glaumann H, Weiland O. Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon alpha-2b without sustained response. Scand J Infect Dis 1994;26:383-389.